Recently, I attended the 2026 Perrin Conferences PFAS Litigation and Regulatory Developments Conference, where industry leaders and practitioners explored the…
Dupixent (dupilumab) has been a genuine breakthrough for many families. For children with moderate-to-severe eczema, asthma, and other inflammatory conditions,…
Regulators worldwide are grappling with how to address the alleged risks artificial intelligence (“AI”)-powered chatbots and virtual companions pose, including…